| Literature DB >> 30554096 |
Mengru Wang1, Wanhua Liu2, Yanqiu Zhang3, Meng Dang4, Yunlei Zhang5, Jun Tao4, Kun Chen4, Xin Peng1, Zhaogang Teng6.
Abstract
The development of effective targeted therapies for triple negative breast cancer (TNBC) remains a challenge. This targeted drug delivery system used a near-infrared fluorescence dye cyanine 5.5 (Cy5.5) and an ICAM-1 antibody on thioether-bridged periodic mesoporous organosilica nanoparticles (PMOs). The ICAM-1 antibody and cyanine 5.5-engineered PMOs (PMO-Cy5.5-ICAM) offer excellent in vivo and in vitro biocompatibility. The PMO-Cy5.5-ICAM shows a loading capacity up to 400 mg/g of doxorubicin (DOX). The drug release profile of the DOX-loaded targeted delivery system (DOX@PMO-Cy5.5-ICAM) is pH-sensitive. Confocal microscopy showed that the PMO-Cy5.5-ICAM efficiently targets and enters TNBC cells. In in vivo experiments, the DOX@PMO-Cy5.5-ICAM accumulates more in TNBCs than in the control groups and exhibits better therapeutic effects on TNBC; thus, it is a promising treatment strategy for TNBC.Entities:
Keywords: Drug delivery system; ICAM-1; Periodic mesoporous organosilica; Targeted therapy; Triple-negative breast cancer
Mesh：
Substances：
Year: 2018 PMID： 30554096 DOI： 10.1016/j.jcis.2018.12.032
Source DB: PubMed Journal: J Colloid Interface Sci ISSN： 0021-9797 Impact factor: 8.128